Rapid resistance profiling of SARS-CoV-2 protease inhibitors
Abstract
Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (Mpro) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms ("fingerprints") and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
S. A. Moghadasi, E. Heilmann, … R. Harris·Science AdvancesPeer-reviewed·Mar 31, 2023
- Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease
Julia M. Flynn, Qiu Yu J. Huang, … Daniel N. A. Bolon·ACS Infectious DiseasesPeer-reviewed·Jun 30, 2023
- Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro
Y. Zhou, K. A. Gammeltoft, … J. M. Gottwein·bioRxiv·Jun 6, 2022
- A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system
Francesco Costacurta, Andrea Dodaro, … Emmanuel Heilmann·PLoS PathogensPeer-reviewed·Sep 11, 2024
- Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains
Hawa Sophia Bouzidi, Jean‐Sélim Driouich, … Franck Touret·Antiviral ResearchPeer-reviewed·Jan 23, 2024
- Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
Y. Hu, E. M. Lewandowski, … J. Wang·ACS Central SciencePeer-reviewed·Jul 24, 2023